Document is current

Article History

Received: 17 June 2019

Accepted: 30 October 2019

First Online: 29 November 2019

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: <b>Paolo A. Ascierto (PAA):</b> Consultant/advisory relationship – Bristol-Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Array, Merck Serono, Pierre-Fabre, Incyte, NewLink Genetics, Genmab, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofy, Idera, Ultimovacs, Sandoz, Immunocore, 4SC. Research funding – Array, Bristol-Myers Squibb, Roche-Genentech. Travel Support – MSD.<b>Carlo Bifulco (CB):</b> Advisory Boards: PrimeVax. BMS. Stock ownership: PrimeVAx.<b>Luigi Buonaguro (LB):</b> no relevant conflicts of interest to report.<b>Leisha A. Emens (LAE):</b> Consultant for: Vaccinex, Celgene, Bristol Meyers Squibb, AstraZeneca, Amgen, Syndax, Molecuvax, eTHeRNA, Peregrine, Bayer, Gritstone, Medimmune, Abbvie, Genentech/Roche, Replimune, Macrogenics. Grant/Research support from: Genentech/Roche, EMD Serono, Maxcyte, Merck, AstraZeneca, Aduro, Corvus. Under a licensing agreement between Aduro Biotech, and the Johns Hopkins University, the University and Dr. Emens are entitled to milestone payments and royalty on sales of a GM-CSF-secreting breast cancer vaccine. The terms of these arrangements are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.<b>Robert L. Ferris (RLF):</b> Advisory Board/Clinical Trial/Research Funding – Amgen, Astra-Zeneca, Bristol-Myers Squibb, MedImmune, EMD Serono, Oncorus, Inc., PPD (Benitec, Immunicum), Lilly, Merck, Pfizer, Regeneron Pharmaceuticals, Inc., Tesaro, VentiRx Pharmaceuticals. Consulting - Bain Capital Life Sciences, Iovance Biotherapeutics, Inc., Ono Pharmaceutical Co. Ltd.<b>Bernard A. Fox (BAF):</b> Scientific Advisory Board: (Advising/Consulting/Stock) Argos, Bayer, Bristol-Myers Squibb, CellDex Therapeutics, Definiens, Janssen/Johnson & Johnson, Macrogenics, MedImmune/AstraZeneca, PerkinElmer. PrimeVax: stock. UbiVac: Co-founder/CEO/stock. Research Support: Bayer, Bristol-Myers Squibb, Definiens, Janssen/Johnson & Johnson, Macrogenics, MedImmune/AstraZeneca, OncoSec, PerkinElmer, Quanterix, Shimadzu, Ventana/Roche, Viralytics.<b>Greg M. Delgoffe (GMD):</b> Consultant: Pieris Pharmaceuticals, Western Oncolytics. Research Support: Pfizer, Bluebird Bio, TCR2 Therapeutics. Founder and Scientific Advisor: TTMS, Inc.Jérôme Galon (JG): Co-founder and chairman of the scientific advisory board: HalioDx. Collaborative Research Agreement (grants): Perkin-Elmer, IObiotech, MedImmune, Janssen. Participation to Scientific Advisory Boards: BMS, MedImmune, Astra Zeneca, Novartis, Definiens, Merck Serono, IObiotech, ImmunID, Nanostring, Illumina, Northwest Biotherapeutics, Actelion, Amgen, Kite Pharma, Merck MSD. Consultant: BMS, Roche, GSK, Compugen, Mologen, Sanofi.<b>Cesare Gridelli (CG):</b> MSD, BMS, Roche, Astra Zeneca.<b>Marco Merlano (MM):</b> Consulting Activities: Eisai, BMS, MerckSerono, MSD. Honoraria: Novartis, AstraZeneca, MerckSerono, BMS, MSD. Research Funding: Eisai, MerckSerono, BMS. Travel, accomodations, expenses: BMS, MerckSerono, Novartis.Paul Nathan (PN): Astrazeneca, Bristol-Myers Squibb, Immunocore, Ipsen, Incyte, MSD, Merck, Novartis, Pfizer, Pierre Fabre, Roche.<b>Kunle Odunsi (KO):</b> AstraZeneca, Tesaro Pharma, Scientific Advisory Board: Immunovaccine, Celsion, Geneos, Triumvira, Unleash Immuno-Oncolytics, Truvax, Merck. Co-founder: Tactiva Therapeutics.<b>Hideho Okada (HO):</b> Inventor of the EGFRvIII-CAR for which an exclusive licensing agreement has been executed with Novartis Pharma.<b>Chrystal M. Paulos (CMP):</b> Lycera Corp., Obsidian, ThermoFisher.<b>Sandro Pignata (SP):</b> Honoraria from AstraZeneca, Clovis, Merck Sharp & Dohme, Pfizer, PharmaMar, Roche, Tesaro. Research funding from AstraZeneca, Roche.<b>Kurt A. Schalper (KAS):</b> Consulting fees – Celgene, Moderna Therapeutics, Abbvie, AstraZeneca and Shattuck Labs. Research funding– Genoptix/Navigate (Novartis), Vasculox/Tioma, Tesaro, Moderna Therapeutics, TakedaPharmaceuticals, Surface Oncology, Pierre-Fabre Research Institute, Merck, Bristol-Myers Squibb, AstraZeneca and Eli Lilly.<b>Stefani Spranger (SS):</b> Venn Therapeutic, Takeda, Replimune, Ribon, Tango, Arcus, Torque Therapeutics.<b>Giampaolo Tortora (GT):</b> Celgene, Novartis, Merck Serono, Incyte.<b>Hassane Zarour (HZ):</b> Research Contracts From BMS, Merck and Tesaro. Advisory Board: Pierre Fabre, Curis.<b>Lisa H. Butterfield (LHB):</b> Scientific and Medical Advisory Board – Simpatica, StemImmune, SapVax, NextCure, Replimmune, Western Oncolytics, Torque Therapeutics.Sandra Demaria (SD): Advisory Board/Research grant - Lytix Biopharma, Nanobiotix SA. Consultant - AbbVie Inc., AstraZeneca AB, EMD Serono, Cytune Pharma.<b>Igor Puzanov (IP):</b> Consultant – Amgen, Roche, Abbvie.